Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
2.
Rev. esp. cardiol. (Ed. impr.) ; 69(11): 1042-1050, nov. 2016. graf, tab, ilus
Article in Spanish | IBECS | ID: ibc-157510

ABSTRACT

Introducción y objetivos: TBX1 es un factor de transcripción importante en el desarrollo embrionario del corazón. Se desconoce su implicación en el remodelado miocárdico tras infarto agudo de miocardio (IAM) y si es modulable por una terapia con beneficio demostrado como es el bloqueo del receptor mineralocorticoideo. Métodos: Se sometió a IAM a 60 ratas mediante ligadura de la coronaria izquierda: 50 animales fueron aleatorizados a ser sacrificados pasadas 1, 2, 4, 12 o 24 semanas; 10 animales se trataron con eplerenona (100 mg/kg/día) 7 días antes del IAM, hasta su sacrificio (4 semanas después); 8 animales se sometieron a cirugía sin ligadura (control). Se analizó la expresión cardiaca de TBX1, genes fetales y marcadores de fibrosis. Resultados: La expresión génica y proteica de TBX1 se incrementó en el miocardio infartado, con pico de expresión 1 semana tras el IAM (p < 0,01), sin variar en el miocardio no infartado. Los genes fetales y los marcadores de fibrosis también aumentaron, con expresión máxima 4 semanas (p < 0,001) y 1 semana (p < 0,01) tras el IAM respectivamente. La expresión de TBX1 se correlacionó con la de los marcadores de fibrosis (p < 0,01), pero no con los genes fetales. La eplerenona redujo el incremento de TBX1 y la fibrosis inducida tras IAM, que se asociaron con una mejora de función y remodelado ventricular por ecocardiografía. Conclusiones: Estos resultados muestran la reactivación de la expresión de TBX1 e indican su implicación en la fibrosis y el remodelado cardiacos tras el IAM y que puede participar en el beneficio del bloqueo mineralocorticoideo (AU)


Introduction and objectives: The transcription factor TBX1 plays an important role in the embryonic development of the heart. Nothing is known about its involvement in myocardial remodeling after acute myocardial infarction (AMI) and whether its expression can be modulated by a treatment with proven benefit such as mineralocorticoid receptor blockade. Methods: Acute myocardial infarction was induced in 60 rats via left coronary artery ligation: 50 animals were randomized to be euthanized after 1, 2, 4, 12, or 24 weeks; 10 animals were treated with eplerenone (100 mg/kg/days) 7 days before the AMI until their euthanasia (4 weeks later); 8 additional animals underwent surgery without ligation (control). We analyzed the cardiac expression of TBX1, fetal genes, and fibrosis markers. Results: The gene and protein expression of TBX1 was increased in the infarcted myocardium, peaking 1 week after AMI (P < .01), without changes in the non-infarcted myocardium. Levels of the fetal genes and fibrosis markers also increased, peaking 4 weeks (P < .001) and 1 week (P < .01) after AMI, respectively. The TBX1 expression was correlated with that of the fibrosis markers (P < .01) but not the fetal genes. Eplerenone reduced the TBX1 increase and fibrosis induced by AMI, with an association improvement in ventricular function and remodeling in echocardiography. Conclusions: These results show the reactivated expression of TBX1 and indicate its involvement in cardiac fibrosis and remodeling after AMI and its participation in the benefit from mineralocorticoid receptor blockade (AU)


Subject(s)
Animals , Rats , Ventricular Remodeling , Myocardial Infarction/physiopathology , Transcription Factors/physiology , Biomarkers/analysis , Mineralocorticoid Receptor Antagonists/therapeutic use , Disease Models, Animal , Fibrosis/physiopathology
4.
Rev Esp Cardiol (Engl Ed) ; 69(11): 1042-1050, 2016 Nov.
Article in English, Spanish | MEDLINE | ID: mdl-27422448

ABSTRACT

INTRODUCTION AND OBJECTIVES: The transcription factor TBX1 plays an important role in the embryonic development of the heart. Nothing is known about its involvement in myocardial remodeling after acute myocardial infarction (AMI) and whether its expression can be modulated by a treatment with proven benefit such as mineralocorticoid receptor blockade. METHODS: Acute myocardial infarction was induced in 60 rats via left coronary artery ligation: 50 animals were randomized to be euthanized after 1, 2, 4, 12, or 24 weeks; 10 animals were treated with eplerenone (100 mg/kg/days) 7 days before the AMI until their euthanasia (4 weeks later); 8 additional animals underwent surgery without ligation (control). We analyzed the cardiac expression of TBX1, fetal genes, and fibrosis markers. RESULTS: The gene and protein expression of TBX1 was increased in the infarcted myocardium, peaking 1 week after AMI (P < .01), without changes in the noninfarcted myocardium. Levels of the fetal genes and fibrosis markers also increased, peaking 4 weeks (P < .001) and 1 week (P < .01) after AMI, respectively. The TBX1 expression was correlated with that of the fibrosis markers (P < .01) but not the fetal genes. Eplerenone reduced the TBX1 increase and fibrosis induced by AMI, with an association improvement in ventricular function and remodeling in echocardiography. CONCLUSIONS: These results show the reactivated expression of TBX1 and indicate its involvement in cardiac fibrosis and remodeling after AMI and its participation in the benefit from mineralocorticoid receptor blockade.


Subject(s)
Myocardial Infarction/genetics , Myocardium/pathology , RNA, Messenger/metabolism , T-Box Domain Proteins/genetics , Ventricular Remodeling/genetics , Actinin/genetics , Actinin/metabolism , Animals , Atrial Natriuretic Factor/genetics , Atrial Natriuretic Factor/metabolism , Blotting, Western , Eplerenone , Fibrosis , Gene Expression Regulation, Developmental , Heart/drug effects , Mineralocorticoid Receptor Antagonists/pharmacology , Myocardium/metabolism , Myosin Heavy Chains/genetics , Myosin Heavy Chains/metabolism , Natriuretic Peptide, Brain/genetics , Natriuretic Peptide, Brain/metabolism , RNA, Messenger/drug effects , Rats , Real-Time Polymerase Chain Reaction , Spironolactone/analogs & derivatives , Spironolactone/pharmacology , T-Box Domain Proteins/drug effects , T-Box Domain Proteins/metabolism , Ventricular Remodeling/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...